Related Experiment Videos

Experimental therapy of human glioma by means of a genetically engineered virus mutant

R L Martuza1, A Malick, J M Markert

  • 1Molecular Neurogenetics Laboratory, Harvard Medical School, Massachusetts General Hospital-East, Charlestown 02129.

Science (New York, N.Y.)
|May 10, 1991
PubMed

Insights

A genetically engineered herpes simplex virus-1 (dlsptk) showed promise in treating malignant gliomas. This virus inhibited glioma growth in cell cultures and animal models, suggesting its potential as a novel cancer therapy.

Area of Science:

  • Neuro-oncology
  • Virology
  • Oncolytic virus therapy

Background:

  • Malignant gliomas represent the most prevalent and fatal type of brain tumor.
  • Current treatment options for malignant gliomas have limited efficacy.

Purpose of the Study:

  • To evaluate the efficacy of a thymidine kinase-negative mutant of herpes simplex virus-1 (dlsptk) as a potential treatment for malignant gliomas.

Main Methods:

  • Testing dlsptk against human glioma cell lines in vitro.
  • Assessing the effect of dlsptk on U87 human gliomas implanted in nude mice (subcutaneous, subrenal, and intracranial models).

Main Results:

  • dlsptk demonstrated direct cytotoxicity against human glioma cell lines in culture.
  • Intratumoral inoculation of dlsptk led to growth inhibition of subcutaneous and subrenal gliomas in nude mice.
  • Intracranial gliomas in nude mice showed prolonged survival following dlsptk treatment.

Conclusions:

  • The genetically engineered virus dlsptk exhibits significant anti-glioma activity.
  • dlsptk warrants further investigation as a potential oncolytic agent for malignant gliomas.

Related Concept Videos